BOSTON, MA, Axonis Therapeutics, a biotechnology company, announced the successful completion of an oversubscribed $115 million Series A financing.
Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis’ lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for inhibitory neurotransmission, for the treatment of epilepsy and pain.
Cormorant Asset Management and venBio Partners co-led the financing with significant investments from Sofinnova Investments, MRL Ventures Fund, Perceptive Advisors, Lumira Ventures and Solasta Ventures.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
By VC News Daily
Source: VC News Daily
Discover more from FundingBlogger
Subscribe to get the latest posts sent to your email.